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The activation of the cGMP-dependent protein kinase and CAMP-dependent protein kinase by the diastereomers of guanosine 3’,5’-monophos- 
phorothioate, (Sp)-cGMPS and (Rp)-cGMPS, and I-chloroguanosine 3’,5’-monophosphorothioate, (Sp)&CltGMPS and (Rp)-8-Cl-cGMPS, was 
investigated using the peptide Kemptide as substrate. The (Sp)-diastereomers, which have an axial exocyclic sulfur atom, bound to the &IMP- 
dependent protein kinase and stimulated its phosphotransferase activity. In contrast, the (Rp)-isomers, which have an equatorial exocyclic sulfur 
atom, bound to the enzyme without stimulation of its activity. (Rp)-cGMPS and (Rp)-8-Cl-cGMPS antagonized the activation of the cGMPde- 
pendent protein kinase with a Ki of 20 PM and 1.5 PM, respectively. (Rp)-cGMPS also antagonized the activation of CAMP-dependent protein 
kinase with a Ki of 20 PM. In contrast, (Rp)-8-Cl-cGMPS was a weak inhibitor of the CAMP-dependent protein kinase with a Ki of 100 pM. (Rp)-8- 
Cl-cGMPS appears to be a rather selective inhibitor of the cGMP-dependent protein kinase and may be a useful tool for studying the role of 
cGMP in broken and intact cell systems. 
Protein kinase, cGMP-dependent; Antagonist; cGMPS; 8-Cl-cGMPS 
1. INTRODUCTION 
cGMP-dependent protein kinase (cGK) from bovine 
lung is a dimer composed of two identical subunits of 
75 kDa each [l]. cGK is considered to be important for 
the regulation of cerebellar Purkinje cells, smooth 
muscle cells, platelets and intestinal epithelial cells [2]. 
Activation of this enzyme occurs upon binding of four 
molecules of cGMP according to the following equa- 
tion [3]: 
E2 + 4 cGMP ;=r E2 - cGMP4 
Each cGK monomer contains one catalytic site and 
two cGMP-binding sites with different affinities for 
cGMP and its analogs [4]. In our search for useful in- 
hibitors for cGK we synthesized (Rp)- and (Sp)-cGMPs 
as well as (Rp)- and (Sp)-8-Cl-cGMPS using a new 
method [5] which improved the yield of these 
nucleotides in comparison to that obtained by other 
methods reported earlier [6-81. Additional reactions 
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were used to remove trace contaminants of cGMP. The 
selection of the stereoselective thiomodification was 
based on our experience with the homologous CAMP- 
dependent protein kinase (cAK). (Rp)-CAMPS is an an- 
tagonist of cAK and thus of CAMP-regulated processes 
including CAMP-regulated gene expression [9- 131. 
Recently, interaction of phosphorothioate derivatives 
of cGMP with the phosphodiesterase and the light- 
sensitive channel from rod outer segments [14] as well 
as the effects of these analogs on starfish oocyte 
maturation [12] were reported. In this study, the effects 
of highly purified diastereomers of cGMPS and &Cl- 
cGMPS on the activity of cGK and type II cAK were 
investigated. 
2. MATERIALS AND METHODS 
2.1. Materials 
The cGK and type II cAK (EC 2.7.1.37) were purified from bovine 
lung and bovine heart, respectively, as described previously [IS]. All 
cyclic nucleotides were synthesized and purified in our laboratory 
[5,16]. The purity was >99.8% as observed by HPLC, and all 
phosphorothioates were free of contamination by the corresponding 
cyclic nucleotides within the detection limit of HPLC. [Y-~~P]ATP 
was from Amersham and the peptide Leu-Arg-Arg-Ala-Ser-Leu-Gly 
(Kemptide) was purchased from Peninsula. Calmodulin-sensitive 
cyclic nucleotide phosphodiesterase (cPDE) from bovine heart (EC 
3.1.4.1) was obtained from Sigma Chemicals. Centricon 10 was from 
Amicon GmbH, Witten, FRG. 
2.2. cPDE assay 
(Rp)-cGMPS and (Rp)-8-Cl-cGMPS are resistant o hydrolysis by 
different cPDEs [14,17,18]. Therefore, cGMP impurities can be 
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removed by incubation with this enzyme [191. For complete elimina- 
tion of traces of cGMP in the cGMP derivatives, 1 cmol of the 
analog was incubated in the presence of 1 U/ml cPDE in 50 mM 
Tris/HCl buffer @H 7.5), 0.1 mM MgClr for 30 min at 30°C. At the 
end of the incubation, the nucleotide was separated from the enzyme 
by filtration using Centricon 10. This treatment significantly reduced 
the partial activation of cGK which was variably observed with high 
concentrations (50pM and higher) of some (Rp)-cGMP analogs 
tested. 
2.3. Protein kinase assay 
Protein kinase activity of cGK or cAK was measured using the 
phosph~elluiose method (201 with minor modifications. Briefly, 
protein kinase activity was assayed at 30°C in a total volume of 100 pll 
containing 20 mM Tris/HCl buffer (pH 7.4), 10 mM MgC12, 5 mM 
,&mercaptoethanol, 0.01% (w/v) bovine serum albumin, 1Opg 
Kemptide (130rM), 50 or 100 ng protein kinase and cyclic 
nucleotides as indicated. The reaction was started by the addition of 
50sM [~-“2P]ATP (about 100 cpm/pmol) and terminated after 
5 min by the addition of 0.1 M EDTA. Activity is expressed as 
amount of phosphate transferred per min and mg protein kinase. 
3. RESULTS AND DISCUSSION 
The structures of the cGMP-an~ogs are shown in 
Fig. 1. The concentration~ependent effects of cGMP, 
(Rp)-cGMPS and (Sp)-cGMPS on the activity of cGK 
are demonstrated in Fig. 2. The apparent activation 
constants K, (cyclic nucleotide concentration required 
for half-maximal activation) as well as the relative ac- 
tivation constants Ka’ [Kk = Ka(c~~p)/K~(~d,,~j] for the 
cyclic nucleotides tested are listed in Table I. The 
relative activation constant describes the activation 
potency of an analog compared to cGMP as activator. 
The data indicate that (Sp)-cGMPs is an agonist with 
respect o the activation of cGK although it is 135 times 
less potent than cGMP (Table I). In contrast, (Rp)- 
cGMPS does not activate the cGK (Fig. 2) and is a 
competitive inhibitor (-Ki = 20 pM) for the cyclic 
nucleotide-dependent activation of cGK (Fig. 3). 
Therefore, (Rp)-cGMPS binds to the cGK, but ap- 
parently does not cause the conformational change of 
the enzyme required for its activation. Similar effects 
( Rp) -cCMPS (Sp)-cGMPS 
~~~~ “.__~~~ 
OH OH 
c Rp)-8-CL-cCHPS c 
‘*~~a$(-~~~?xq 
OH OH 
Fig. 1. Structures of (Rp)- and (Sp)-3 ~,S’-monophosphorothioates of 
cGMP and 8-Cl-cGMP. 
Table I 
Activation and inhibition constants for bovine lung cGK 
Cyclic nucleotide 
Bovine lung cGMP-dependent protein kinase 
I (M) Kl Ki (Ml 
cGMP 2.0 x lo-’ 1.0 
(Sp)-cGMPS 2.7 x 10-s 0.007 
(Rp)-cGMPS antagonist 2 x 10-5 
S-Cl-cGMP 7.3 x 10-S 2.7 
(Sp)-S-CI-cGMPS 3.4 x IO-+ 0.057 
fRp)-S-Cl-cGMPS antagonist 1.5 x IO+ 
CAMP 3.9 x 10-s 0.005 
(Sp)-CAMPS antagonist 
(partial agonist) - 7.3 x 1o-5 
(Rp)-CAMPS antagonist 5.3 x 10-s 
Apparent activation constants Ka (concentrations required for half- 
maximal activation), relative activation constants K: 
[Ka(c~~~)/Ka(tios)l, or inhibition constants Kt of cGMP and some 
analogs for bovine lung cGK. Similar results were obtained in three 
separate experiments. The data for (Sp)-CAMPS and (Rp)-cAMPS 
were reported by Hofmann et al. 1211 
were observed when 8-Cl-substituted derivatives of 
cGMPS were used. (Sp)-8-Cl-cGMPS activated the 
cGK with a & of 3.4 pM while the (Rp)-diastereomer 
was an antagonist with a Ki of 1.5 PM (Table I). As 
observed with cGMP, &Cl-substitution of (Sp)-cGMPS 
increased the affinity of this analog for the cGK (Table 
I); [171). 
The (Sp)-diastereomers which have an axial exocyclic 
sulfur atom in the cyclic phosphate moiety bound to the 
cGK with a reduced affinity and acted as agonists. 
(Rp)-derivatives with an equatorial exocyclic sulfur 
atom bound to the enzyme and were antagonists. The 
same effect has previously been observed with the cAK 
I and cAK II and the (Sp)- and (Rp)-diastereomers of 
CAMPS. Interestingly, both (Sp)- and (Rp)- 
phosphorothioate stereoisomers of CAMP are known 
to antagonize the activation of cGK [21], although with 
rather low inhibition constants when compared to 
OL//: 
0 -8 -7 -0 -5 -4 -3 
log Cyclic Nucleotidc (M) 
Fig. 2. Effects of cGMP (r). (Sp)-cGMPS (a), and (Rp)-cGMPS 
(e) on the activity of CGMP-dependent protein kinase. The activity 
of the enzyme in the absence of cyclic nucleotides is indicated (0). 
Similar data were obtained in several separate xperiments. 
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Fig. 3. Dixon plot demoustrating the competitive inhibition by (Rp)- 
cGMPS of the cGMP-induced activation of cGK. l/V is the 
reciprocal value of the phosphotransferase activity 
@mol. mm-‘. mg-‘) measured. Similar results were obtained in three 
separate experiments. 
(Rp)-8-Cl-cGMPS (Table I). These data indicate that 
the exocyclic oxygens of the cyclic phosphate are very 
important for the mechanism of binding and activation 
of cyclic nu~l~~de-dependent protein kinases. In this 
respect, cAK and cGK have similar properties. 
Therefore, the phosphorothioat~ stereoisomers of 
cGMP were also tested with respect to their effects on 
the type II cAK. Surprisingly, (Sp)-stereoisomers of 
cGMPS and 8-Cl-cGMPS were better activators of cAK 
than cGMP and &Cl-cGMP, respectively (Table II). 
(Rp)-cGMPS and (Rp)-8-Cl-cGMPS were inhibitors of 
bovine heart type II cAK, however, they had a reduced 
binding affinity when compared to (Rp)-CAMPS (Table 
II), 
In conclusion, (Rp)~GMPS is a moderately effective 
antagonist for both cGK and cAK while (Rp)-8X1- 
cGMPS is a potent and reasonably selective inhibitor of 
the cCK. (Rpf- and (Sp)-cGMPS as well as the 8-Cl- 
Table II 
Activation and inhibition constants for bovine heart type II cAK 
Type II CAMP-dependent protein kinase 
Cyclic nucleotide & (MI K: K Ml 
CAMP 1 X to-’ 1.0 
cGMP 6 X 10-J 0.0016 
[Sp)-cGMPS 2.7 X 10-S 0.003 
(Rp)-cGMPS antagonist 2 X IO-5 
8-Cl-cGMP 6.5 x IO-’ 0.0015 
(Sp)-8-Cl-cGMPS 8.3 x 10-6 0.012 
(Rp)-8-Cl-cGMPS antagonist IO x 10-s 
&+&AMPS 1.8 x lO+ 0.056 
(Rp)-CAMPS antagonist 3.7 x 10-6 
Apparent activation constants K. (concentrations required for half- 
maximal activation), relative activation constants K: 
[&~~p)/xT,(,ti,r& or inhibition constants K; of CAMP, cGMP and 
some analogs for bovine heart type ff cAK. Similar results were 
obtained in three separate experiments. The data for (Sp)-cAMPS 
and (Rp)-CAMPS were reported by Van Haastert et al. f22J and were 
obtained with type If cAK from rabbit muscle 
substituted diastereomers of these nudeotides should 
be valuable tools for the investigation of cGMP- 
regulated biological processes. In particular, this will be 
of interest with respect to cGMP-regulated cyclic 
nucleotide phosphodiesterases [23] and cGMP- 
regulated ion channels 1241 as well as other types of 
cGMP-dependent protein kinase [Z] than the one 
studied here. Phosphorothioate analogs such as (Sp)- 
and (Rp)-~-Cl-IMPS are not only effective activators 
or inhibitors, r~~~tively~ of &K (this study), but 
these analogs are also resistant to hydrolysis by 
phosphodiesteras~ and have a Iipophilicity which is 
similar to that of 8-bromo-cGMP and much higher 
than that of cGMP [17]. Therefore, these diastereomers 
should be of considerable interest for studies in- 
vestigating cGK-controlled functions with intact cells 
such as regulation of smooth muscle calcium concen- 
tration or nitrovasodilator-induced protein 
phosphorylation [25,26]. 
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